Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00843349 · ClinicalTrials.gov registry record · NA
Fibroblast Growth Factor-23 (FGF23) Reduction in Predialysis Chronic Kidney Disease (CKD)
A NA study of Kidney Disease, sponsored by Myles Wolf.
- Completed
- Registry status
- NA
- Development phase
- 43
- Enrollment target
- 1
- Study location
NCT00843349: Completed NA study of Kidney Disease, sponsored by Myles Wolf.
NCT00843349 is a NA study of Kidney Disease that has completed, run by Myles Wolf. The registered enrollment target is 43 participants, below the 2,938-participant average among 23 other Kidney Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00843349, a NA study of Kidney Disease, has completed, sponsored by Myles Wolf.
- COMPLETED
- Registry status
- NA
- Development phase
- 43 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators would like to study the role of phosphorus metabolism in the development of certain hormonal problems in people with chronic kidney disease (CKD). More specifically, the goals of the research are (1) to understand the cause of hyperparathyroidism - a hormone problem that often develops in patients who have kidney disease and (2) to test whether decreasing phosphorus intake could help improve or prevent hyperparathyroidism.
Primary Outcome
Nonfasting blood was assessed over a period of 12 weeks. The primary endpoint was percentage change in FGF-23 levels from baseline.
Conditions Studied
Interventions
- DRUG Lanthanum Carbonate
- OTHER 900 mg Phosphate Diet
- DRUG LC Placebo
- OTHER Ad Libitum Diet
Study Locations (1)
Florida
- University of Miami Hospital - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2009-07 |
| Est. Completion | 2012-03 |
| Phase | NA |
What the finished NCT00843349 record still lists
NCT00843349 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 2,938-participant average among 23 other Kidney Disease trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Kidney Disease appearing as the primary indexed condition, and to 4 interventions - of which Lanthanum Carbonate is the first listed.
NCT00843349 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT00843349 about?
NCT00843349 is a clinical study titled "Fibroblast Growth Factor-23 (FGF23) Reduction in Predialysis Chronic Kidney Disease (CKD)". The investigators would like to study the role of phosphorus metabolism in the development of certain hormonal problems in people with chronic kidney disease (CKD). More specifically, the goals of the research are (1) to understand the cause of hyperparathyroidism - a hormone problem that often deve...
What is the current status of trial NCT00843349?
This trial is currently completed. It is a NA study. The enrollment target is 43 participants. The study started on 2009-07. Estimated completion is 2012-03.
What conditions does trial NCT00843349 study?
This clinical trial studies the following conditions: Kidney Disease.
What interventions are being tested in trial NCT00843349?
The interventions under investigation include: Lanthanum Carbonate (DRUG), 900 mg Phosphate Diet (OTHER), LC Placebo (DRUG), Ad Libitum Diet (OTHER).
Who is sponsoring clinical trial NCT00843349?
This trial is sponsored by Myles Wolf, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00843349 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00843349's enrollment target sits among peer trials
43 17th of 23 higher than 7 of 23 other Kidney Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Kidney Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Cardiovascular Kidney and Metabolic Health Assessment and Patient Empowerment
RECRUITING · NA
-
Inspire HER: Inspiring the Heart and Emotions for Radical Health
RECRUITING · NA
-
Outcomes of Physiologic Insulin Resensitization (PIR) in Patients With Chronic Kidney Disease and Type 2 Diabetes Mellitus
RECRUITING · NA
-
Prevention of Secondary Hyperparathyroidism With Vitamin D in Stage II/III Chronic Kidney Disease
COMPLETED · NA
-
Pediatric Acute Kidney Injury (AKI) Retrospective, Real-Time and Repository Research
COMPLETED · NA
-
Rutgers University Study of the Genetics of Kidney Disease
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia